TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment

Model scores of the 29,894 trials active now.

Model score 36% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-07-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientpatients mustmetastaticchemotherapyradiotherapy
  Phrases that lowered it: aminotransferaseopenrandomisedlong termthe efficacy
• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 29.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 97.3% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 39032 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma NCT01883323 · started 2013 · scored riskier than 99% of active trials completed
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma NCT02278887 · started 2014 · scored riskier than 97% of active trials completed
• Intratumoral Application of L19IL2 in Patients With Malignant Melanoma NCT01253096 · started 2010 · scored riskier than 99% of active trials completed
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma NCT02111863 · started 2014 · scored riskier than 99% of active trials terminated
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... NCT01319565 · started 2011 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.